Under the Amendment, the Company obtained an incremental term loan in an aggregate principal amount of $350.0 million.
 The unaudited pro forma financial information presented in the table above has been adjusted to give effect to adjustments that are (1) directly related to the acquisition; (2) factually supportable; and (3) expect to have a continuing impact.
The Company records commitment fees and other costs directly associated with obtaining line of credit financing as deferred financing costs which are presented within "Other assets" in the accompanying unaudited Consolidated Balance Sheets.
The principal is payable in installments equal to 0.25% of the initial principal amount of the term loans on March 31st, June 30th, September 30th and December 31st of each year, commencing on March 31, 2018, with any remaining amount of principal becoming due and payable on the maturity date.
 The Company adopted this standard effective October 1, 2018, using the modified retrospective method and has only applied this method to contracts that were not completed as of the effective date and all new contracts initiated on or after the effective date.
 In connection with the GENEWIZ acquisition, we assumed three five-year term loans for a total of $3.3 million and two one-year short term loans for a total of RMB 22 million or $3.2 million.
   ·    Identify the performance obligations in the contract.
 The total cash purchase price for the acquisition was $442.7 million, net of cash acquired, which included a working capital settlement of $0.4M.
The guidance provides for the recognition of revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services.
On November 15, 2018, the Company entered into an incremental Amendment (the “Amendment”) to the existing credit agreement.
The ASU does not amend the interim disclosure requirements of ASC 715-20.
 On August 27, 2018, the Company entered into a definitive agreement to sell its semiconductor cryogenics business to Edwards Vacuum LLC (a member of the Atlas Copco Group) for $675.0 million in cash.Cost of revenue for the three and six months ended March 31, 2019 included $2.8 million and $4.8 million, respectively, of charges for amortization related to completed technology as compared to $1.0 million and $1.9 million, respectively, during the corresponding periods of the prior fiscal year.
 Our Brooks Semiconductor Solutions Group segment reported gross margins of 40.7% for the three months ended March 31, 2019 as compared to 40.1% for the corresponding period of the prior fiscal year.
The specific terms of any securities to be sold will be described in supplemental filings with the SEC.
The increase in interest expense is due to interest on the $350.0 million incremental term loan secured in the first quarter of fiscal year 2019 used to pay a portion of the purchase price for our acquisition of GENEWIZ.
As of March 31, 2019 and September 30, 2018, we had marketable securities of $2.8 million and $53.5 million, respectively.
 Our Brooks Semiconductor Solutions Group segment reported gross margins of 40.7% for the three months ended March 31, 2019 as compared to 40.1% for the corresponding period of the prior fiscal year.